March 17, 2020 / 11:42 AM / 11 days ago

BRIEF-Novus Therapeutics Posts Q4 Loss Per Share $0.32

March 17 (Reuters) - Novus Therapeutics Inc:

* NOVUS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

* Q4 LOSS PER SHARE $0.32

* HAD APPROXIMATELY $8.8 MILLION IN CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2019

* NOVUS THERAPEUTICS - EXPECT TO ANNOUNCE DATA FROM FULLY ENROLLED PHASE 2A EFFICACY STUDY IN INFANTS & CHILDREN WITH ACUTE OTITIS MEDIA IN COMING MONTHS

* NOVUS THERAPEUTICS - DATA FROM FULLY ENROLLED PHASE 2A EFFICACY STUDY IN INFANTS & CHILDREN WITH ACUTE OTITIS MEDIA TO BE ANNOUNCED BY EARLY JUNE 2020

* NOVUS THERAPEUTICS - CO’S CASH AND CASH EQUIVALENTS EXPECTED TO FUND OPERATIONS THROUGH YEAR END 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below